NCT06501651Not yet recruitingPhase 4
A Prospective, Randomized, Controlled, Multicenter Study of Sacubitril/Valsartan in the Treatment of Patients With Mild to Moderate Essential Hypertension and Type 2 Diabetic Nephropathy: The Hyper-Save Study
Sichuan Academy of Medical Sciences1 site in 1 country297 target enrollmentStarted: August 1, 2024Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 4
- Status
- Not yet recruiting
- Enrollment
- 297
- Locations
- 1
- Primary Endpoint
- Reduction in 24-hour ambulatory systolic blood pressure(SBP)
Study Overview
Brief Summary
This study aims to compare the efficacy and safety of Sacubitril/Valsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period, including two treatment groups, with a total of 297 eligible subjects randomly assigned in a 2:1 ratio to either the experimental group or the control group.Subjects will participate in the study through two phases: the screening period and the follow-up period.The primary outcome measure is the change in systolic blood pressure from baseline after 12 weeks of treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age 18 years or older, no gender restriction;
- •Diagnosed with mild to moderate primary hypertension (140 ≤ SBP < 180 mmHg and/or 90 ≤ DBP < 110 mmHg), including newly diagnosed or inadequately treated patients (those who have not followed previous medical advice and have uncontrolled blood pressure according to the investigator);
- •Diagnosed with type 2 diabetes (according to Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)), and meeting the following conditions: a) Continuously on ≥ 1 glucose control medication regimens (which may include long-acting insulin) for at least 12 weeks before screening, with a stable treatment regimen (i.e., the same medication and dosage) for at least 28 days before screening, and maintaining this regimen during the study. At the investigator's discretion, the dose of supplemental short-acting insulin can be adjusted as needed to achieve adequate glucose control; b) HbA1c level ≤ 10.5% and fasting (≥ 8 hours) plasma glucose level ≤ 13.3 mmol/L (if fasting glucose > 13.3 mmol/L, the investigator may repeat the test to determine eligibility);
- •Urine albumin/creatinine ratio (UACR) ≥ 30 mg/g in two measurements taken on separate days or eGFR < 60 mL/min/1.73 m²;
- •Non-pregnant or fertile patients (male or female) using reliable contraception;
- •Female patients with potential for pregnancy must have a negative pregnancy test at screening;
- •Subjects must voluntarily agree to comply strictly with the study protocol requirements and sign a written informed consent form.
Exclusion Criteria
- •Presence of severe hypertension, malignant hypertension, hypertensive emergencies, or hypertensive crises;
- •History or evidence of secondary hypertension within 12 months before screening, including but not limited to any of the following: renovascular hypertension, renal parenchymal hypertension, unilateral or bilateral renal artery stenosis, coarctation of the aorta, primary aldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension;
- •History of angioedema (drug-related or other causes) within 12 months before screening;
- •Presence of diabetic ketoacidosis;
- •History or evidence of secondary diabetes within 12 months before screening, including but not limited to any of the following: endocrine disorders causing carbohydrate metabolism disorders, pancreatogenic diabetes, hepatogenic diabetes, nephrogenic diabetes, etc.;
- •History of malignancy in any organ system (excluding localized basal cell carcinoma of the skin);
- •History of acute stroke, lacunar infarction, or dementia within 6 months before screening;
- •History of coronary artery bypass graft surgery or any percutaneous coronary intervention (PCI) within 6 months before screening;
- •Previously diagnosed or currently diagnosed heart failure (NYHA Class III-IV) or clinically significant valvular heart disease;
- •History or current diagnosis of cardiac abnormalities: (1) second or third-degree atrioventricular block without a pacemaker; (2) clinically significant arrhythmias, including atrial fibrillation with a ventricular rate ≥ 120 bpm; (3) family history of long QT syndrome or torsades de pointes ventricular tachycardia;
- •Chronic kidney disease stage 4 or higher (eGFR < 30 mL/min/1.73 m²), receiving renal dialysis, or history of kidney transplantation;
- •Significant abnormalities in laboratory tests, such as potassium levels > 5.5 mmol/L or < 3.5 mmol/L, sodium levels < 130 mmol/L, liver function (ALT, AST) results > 3 times the upper limit of normal;
- •History of allergy to antihypertensive drugs such as ARBs, Angiotensin-Converting Enzyme (ACE) inhibitors, or renin inhibitors;
- •Clear history of intolerance to drugs similar to the study medication (e.g., ACE inhibitors, ARBs);
- •Use of traditional Chinese or Western medicines that could affect the study's efficacy during the study period (see appendix for list);
- •Any surgery or medical condition that significantly alters the absorption, distribution, metabolism, or excretion of any medication, including but not limited to the following: clinically significant gastrointestinal surgery within 12 months before the screening (e.g., gastrectomy, gastrointestinal anastomosis, bowel resection, gastric bypass, gastroenterostomy, or gastric banding), current active inflammatory bowel disease or history of active inflammatory bowel disease;
- •Pregnant or breastfeeding women, or patients of childbearing potential unwilling or unable to use effective contraception during the study period;
- •Participation in another clinical study using any investigational drug or observational study within 30 days before screening;
- •Other conditions that, in the investigator's judgment, may affect the conduct of the clinical study or the determination of study results.
Arms & Interventions
Experimental
Experimental
Initial Dose: The starting dose of Sacubitril/Valsartan is 200 mg once daily. Dose Adjustment: If blood pressure targets (SBP < 130 mmHg and DBP < 80 mmHg) are not achieved after 2 weeks of treatment, the dose of Sacubitril/Valsartan should be doubled to 400 mg once daily.
Additional Treatment: If blood pressure targets are still not met after an additional 2 weeks of treatment, Nifedipine controlled-release tablets (30 mg once daily) should be added to the regimen.
Intervention: Sacubitril/Valsartan (Drug)
Comparator
Active Comparator
Initial Dose: The starting dose of Valsartan is 80 mg once daily. Dose Adjustment: If blood pressure targets (SBP < 130 mmHg and DBP < 80 mmHg) are not achieved after 2 weeks of treatment, the dose of Valsartan should be doubled to 160 mg once daily.
Additional Treatment: If blood pressure targets are still not met after an additional 2 weeks of treatment, Nifedipine controlled-release tablets (30 mg once daily) should be added to the regimen.
Intervention: Valsartan (Drug)
Outcomes
Primary Outcomes
Reduction in 24-hour ambulatory systolic blood pressure(SBP)
Time Frame: From enrollment to the end of treatment at 12 weeks
The comparison of the reduction in 24-hour ambulatory systolic blood pressure from baseline between the two groups
Secondary Outcomes
- Reduction in 24-hour ambulatory diastolic blood pressure(DBP)(From enrollment to the end of treatment at 12 weeks)
- Changes in daytime and nighttime ambulatory blood pressure(From enrollment to the end of treatment at 12 weeks)
- Improvement in diabetes condition(From enrollment to the end of treatment at 12 weeks)
- Rate of blood pressure achievement(From enrollment to the end of treatment at 12 weeks)
- Medication utilization(From enrollment to the end of treatment at 12 weeks)
- Safety assessments(From enrollment to the end of treatment at 12 weeks)
- Rate of dipper blood pressure restoration(From enrollment to the end of treatment at 12 weeks)
- Improvement in Renal Function(From enrollment to the end of treatment at 12 weeks)
- Rate of hypertension treatment response(From enrollment to the end of treatment at 12 weeks)
Investigators
tianwenjie1976
Chief Physician
Sichuan Academy of Medical Sciences
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARBAortic Valve InsufficiencyNCT05212597Samsung Medical Center100
Active, not recruiting
Phase 4
Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)Heart FailureNCT05164653Saga University400
Completed
Phase 4
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.Heart Failure, Reduced Ejection FractionNCT02970669Novartis Pharmaceuticals140
Completed
Phase 4
Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCCHeart FailureChagas DiseaseNCT04023227Novartis Pharmaceuticals922
Completed
Phase 4
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection FractionHeart Failure and Reduced Ejection FractionNCT02874794Novartis Pharmaceuticals465